MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.120
+0.020 (1.82%)
Nov 7, 2025, 4:00 PM EST - Market closed
Company Description
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312 416 8592 |
| Website | maiabiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial and Accounting Officer |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | 8-K | Current Report |
| Oct 27, 2025 | 8-K | Current Report |
| Oct 24, 2025 | 8-K | Current Report |
| Oct 23, 2025 | 8-K | Current Report |
| Oct 14, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 14, 2025 | 8-K | Current Report |
| Oct 7, 2025 | 8-K | Current Report |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 24, 2025 | 8-K | Current Report |